Targeting mechanisms of Pseudomonas aeruginosa pathogenesis

被引：243

作者：

Kipnis, E ^{[1
]}

Sawa, T ^{[1
]}

Wiener-Kronish, J ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA

来源：

MEDECINE ET MALADIES INFECTIEUSES | 2006年 / 36卷 / 02期

关键词：

Pseudomonas aeruginosa; pathogenicity; virulence factors;

D O I：

10.1016/j.medmal.2005.10.007

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Pseudomonas aeruginosa is an opportunistic pathogen responsible for ventilator-acquired pneumonia, acute lower respiratory tract infections in immunocompromised patients and chronic respiratory infections in cystic fibrosis patients. High incidence, infection severity and increasing resistance characterize P. aeruginosa infections, highlighting the need for new therapeutic options. One such option is to target the many pathogenic mechanisms conferred to P. aeruginosa by its large genome encoding many different virulence factors. This article reviews the pathogenic mechanisms and potential therapies targeting these mechanisms in P. aeruginosa respiratory infections. (c) 2006 Elsevier SAS. All rights reserved.

引用

页码：78 / 91

页数：14

共 172 条

[11] Structural requirements for TLR4-mediated LPS signalling:: a biological role for LPS modifications [J].

Bäckhed, F ;

Normark, S ;

Schweda, EKH ;

Oscarson, S ;

Richter-Dahlfors, A .

MICROBES AND INFECTION, 2003, 5 (12) :1057-1063

[12] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[13]

BOYD A, 1995, J IND MICROBIOL, V15, P162, DOI 10.1007/BF01569821

[14] Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of pseudomonas aeruginosa infections [J].

Burgess, DS .

CLINICAL INFECTIOUS DISEASES, 2005, 40 :S99-S104

[15] Synthetic peptide vaccine development: measurement of polyclonal antibody affinity and cross-reactivity using a new peptide capture and release system for surface plasmon resonance spectroscopy [J].

Cachia, PJ ;

Kao, DJ ;

Hodges, RS .

JOURNAL OF MOLECULAR RECOGNITION, 2004, 17 (06) :540-557

[16] Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection [J].

Cantin, AM ;

Woods, DE .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (04) :1130-1135

[17]

Chastre J, 2000, Semin Respir Infect, V15, P287

[18] Ventilator-associated pneumonia [J].

Chastre, J ;

Fagon, JY .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (07) :867-903

[19] Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P-aeruginosa infection [J].

Chen, TY ;

Shang, HF ;

Chen, TL ;

Lin, CP ;

Hui, CF ;

Hwang, J .

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 1999, 52 (04) :524-533

[20] Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells:: Implications for cystic fibrosis disease [J].

Cobb, LM ;

Mychaleckyj, JC ;

Wozniak, DJ ;

López-Boado, YS .

JOURNAL OF IMMUNOLOGY, 2004, 173 (09) :5659-5670

← 1 2 3 4 5 6 7 8 9 10 →